Hyphens Pharma gets exclusive rights to distribute European autoinjector

It will distributed in Singapore, Malaysia, the Philippines, and Vietnam.

Hyphens Pharma International Limited’s subsidiary, Hyphens Pharma, has obtained an exclusive right to market subcutaneous autoinjector Metoject pen.

Hyphens Pharma signed an agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to distribute in Singapore, Malaysia, the Philippines, and Vietnam for rheumatoid arthritis treatment.

Metoject may also be used for the treatment of plaque psoriasis and has a lower intensity of certain gastrointestinal side effects compared to the oral drug.

The autoinjector pen’s design ensures simple two-step self-injection with an enhanced safety feature of a built-in needle and is available in multiple strengths including 7.5mg, 10mg, and 15mg.

The people you want to reach are already in this room.

Every quarter, SBR lands on the desks of the founders, CFOs, and directors running Asia's most consequential companies. Every day, they open our newsletter and read our website. It's a room that took twenty years to build — and it's the one most of our partners are trying to get into.

The good news is that the door is open. We work with companies on thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. The shape of the right partnership depends on what you're trying to do, which is why we'd rather start with a conversation than send a rate card.

If you have something this room should know about, tell us. We'll tell you honestly whether we can help, and how.

No rate cards until we understand the brief. It's a better use of everyone's time.

Book a meeting

| Or download the media kit (PDF)

240,000 senior readers quarterly in print Top 1,700 Singapore companies reached

7 markets across Southeast Asia